FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:631-634 August 28, 1997 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

On April 10, 1997, the Securities and Exchange Commission filed the first case ever brought against a biomedical researcher on the basis of allegations of insider trading.¹ The case involved a gastroenterologist at Wayne State University who was the lead investigator in a clinical trial of an experimental antihepatitis drug manufactured by Alpha I Biomedicals.² The commission charged that the investigator and his wife illegally alerted at least six friends and relatives that the clinical trial had failed to demonstrate the effectiveness of the drug. On the basis of this disclosure, the six people allegedly sold their Alpha I shares . . . [Full Text of this Article]

The Statutory Framework

The Materiality of Biomedical-Research Results

Who is Subject to the Insider-Trading Laws?

Examples of Insider Trading Based on Biomedical Research

Conclusions

References

This article has been cited by other articles:

• Steinbrook, R. (2005). Wall Street and Clinical Trials. NEJM 353: 1091-1093 [Full Text]